

## Review Article

# Support of drug therapy using functional foods and dietary supplements: focus on statin therapy

Simone Eussen<sup>1,2</sup>, Olaf Klungel<sup>2\*</sup>, Johan Garssen<sup>2</sup>, Hans Verhagen<sup>1</sup>, Henk van Kranen<sup>1</sup>, Henk van Loveren<sup>1</sup> and Cathy Rompelberg<sup>1</sup>

<sup>1</sup>National Institute for Public Health and the Environment (RIVM), PO Box 1, 3720 BA Bilthoven, The Netherlands

<sup>2</sup>Utrecht Institute for Pharmaceutical Sciences, PO Box 80082, 3508 TB Utrecht, The Netherlands

(Received 26 March 2009 – Revised 15 September 2009 – Accepted 5 November 2009 – First published online 3 March 2010)

Functional foods and dietary supplements might have a role in supporting drug therapy. These products may (1) have an additive effect to the effect that a drug has in reducing risk factors associated with certain conditions, (2) contribute to improve risk factors associated with the condition, other than the risk factor that the drug is dealing with, or (3) reduce drug-associated side effects, for example, by restoring depleted compounds or by reducing the necessary dose of the drug. Possible advantages compared with a multidrug therapy are lower drug costs, fewer side effects and increased adherence. In the present review we have focused on the support of statin therapy using functional foods or dietary supplements containing plant sterols and/or stanols, soluble dietary fibre, *n*-3 PUFA or coenzyme Q<sub>10</sub>. We conclude that there is substantial evidence that adding plant sterols and/or stanols to statin therapy further reduces total and LDL-cholesterol by roughly 6 and 10 %, respectively. Adding *n*-3 PUFA to statin therapy leads to a significant reduction in plasma TAG of at least 15 %. Data are insufficient and not conclusive to recommend the use of soluble fibre or coenzyme Q<sub>10</sub> in patients on statin therapy and more randomised controlled trials towards these combinations are warranted. Aside from the possible beneficial effects from functional foods or dietary supplements on drug therapy, it is important to examine possible (negative) effects from the combination in the long term, for example, in post-marketing surveillance studies. Moreover, it is important to monitor whether the functional foods and dietary supplements are taken in the recommended amounts to induce significant effects.

### Combination therapy: Dyslipidaemia: Statins: Functional foods

The world market for functional foods (FF) and dietary supplements (DS) is expanding rapidly. In 2010 FF are expected to represent 5 % of the total global food market<sup>(1)</sup> and the market for DS is estimated at more than \$60 billion worldwide<sup>(2)</sup>. In general, the target population of FF or DS is healthy individuals with slightly elevated risk factors or some physical discomfort. However, due to the fast growing market of FF or DS and the accompanying strong advertising and marketing, also patients on medication may be stimulated to use FF or DS. This may have several consequences for the quality of drug treatment as stated by de Jong *et al.* with the example of the combined intake of plant sterols and/or stanols and statins<sup>(3)</sup>. Whereas they addressed the additive effect of plant sterols and/or stanols on reducing LDL-cholesterol values in patients on statin treatment, their main focus was the possible negative aspects of the combination, such as unfavourable effects on patient adherence with drug treatment and increasing the potential for food–drug interactions.

In the present review we will focus on the possible beneficial effects that FF or DS may have on drug therapy. Because of the large number of subjects treated suboptimally with statins (hydroxymethylglutaryl CoA (HMG-CoA) reductase inhibitors)<sup>(4)</sup> and the availability of several FF and DS possibly contributing to the beneficial effects of statin treatment, we will put special emphasis on this group of drugs.

In theory, FF or DS may support drug therapy in three different ways.

First, FF or DS may add to the effect that a drug has in reducing risk factors associated with certain conditions or diseases. For the example of statin therapy, statins reduce LDL-cholesterol by 18–55 % (mean absolute LDL-cholesterol reduction: 1.8 mmol/l)<sup>(5–8)</sup> and plant sterols and/or stanols and soluble dietary fibres are thought to reduce LDL-cholesterol levels even further when added to the statin treatment.

Second, certain FF or DS may improve risk factors associated with the condition, other than the risk factor that the drug

**Abbreviations:** ABC, ATP-binding cassette; CoQ<sub>10</sub>, coenzyme Q<sub>10</sub>; DS, dietary supplements; EFSA, European Food Safety Authority; FDA, Food and Drug Administration; FF, functional foods; FH, familial hypercholesterolaemia; HC, hypercholesterolaemic; HMG-CoA, hydroxymethylglutaryl CoA; IDL, intermediate-density lipoprotein.

\* **Corresponding author:** Dr O. H. Klungel, fax +31 30 253 9166, email O.H.Klungel@uu.nl

is dealing with. In our example, statins are highly effective in lowering total and LDL-cholesterol, but statin monotherapy may not be sufficient to reach goals for TAG concentrations. Depending on the type of statin and its dose, TAG are lowered only by 7–30%<sup>(5)</sup>. Supplementing patients with *n*-3 PUFA will lower TAG and might improve statin therapy, since both cholesterol and TAG levels are lowered.

Third, FF or DS may be capable of reducing drug-associated side effects, for example, by restoring depleted compounds. With statin treatment, adverse events such as musculoskeletal complaints have been reported in 1–7% of statin users<sup>(9)</sup> and it has been hypothesised that statin-induced coenzyme Q<sub>10</sub> (CoQ<sub>10</sub>) deficiency is involved in this. Supplementing CoQ<sub>10</sub> might reduce musculoskeletal complaints. Besides, in patients who reach recommended goals for risk factors but experience side effects with drug use, combination therapy of the drug and a FF or DS might be an alternative with the potential of reducing the drug dose and as a result the side effects, while levels of risk factors remain constant. Subsequently, it is conceivable that patients experiencing fewer side effects will have a better adherence to drug treatment. Adherence might also be higher with the combination therapy of a FF or DS and a statin compared with a multidrug therapy, as patients might be more willing to slightly modify their diet by replacing normal food items with comparable FF, compared with taking another drug; patients' perception of overmedication has been found to correlate with self-report of decreased adherence<sup>(10)</sup>. Other advantages of the combination therapy with FF or DS compared with multidrug therapy are the lower drug costs and the reduced risk for interactions and serious side effects<sup>(11)</sup>.

For the present review, we reviewed the data from clinical and observational studies that have investigated the effects of the use of FF or DS in patients on statin treatment. We selected four categories: FF or DS containing (1) plant sterols or stanols, (2) soluble dietary fibre, (3) *n*-3 PUFA, and (4) CoQ<sub>10</sub>. We investigated whether these FF or DS have been demonstrated to support statin therapy in one of the three ways described above.

The present review should not be viewed as comprehensive in covering all possible beneficial combination therapies of FF or DS and statins. Rather, the authors' intent is to focus on different mechanisms of action by which FF or DS may support statin treatment and to provide a full coverage of the literature of the examples of combination therapies given.

### Literature search

Computerised searches for relevant articles in the PubMed electronic database were performed between March and August 2008, using Medical Subject Heading (MeSH) terms or text words combi\*, supple\* or interact\* with statin\*, antilipemic agents, anticholesteremic agents or hydroxymethylglutaryl CoA reductase inhibitors, and combined to one of the search items for the specific FF or DS as noted in Table 1. The search was limited to articles written in English or Dutch and studies performed in human subjects. Studies conducted in patients with medical conditions other than hyperlipidaemia, for example, cancer or diabetics, were excluded. Relevant articles were selected from the title and abstract. Moreover, additional articles were selected from citations in

**Table 1.** Literature search

FF or DS	Literature search
Containing plant sterols or stanols	Phytosterol [MeSH], plant sterol*, plant stanol*, phytosterol*, phytostanol*, stanol ester* or sterol ester*
Containing soluble dietary fibre	Dietary fibre [MeSH], dietary fibre, soluble fibre, soluble fibre, beta-glucans [MeSH], psyllium [MeSH], oat*, yeast, barley or pectin
Containing <i>n</i> -3 PUFA	Omega-3 fatty acids [MeSH], omega-3 fatty acid*, w-3 fatty acid*, <i>n</i> -3 fatty acid*, fish oil or marine oil
Containing coenzyme Q <sub>10</sub>	Ubiquinone [MeSH], ubiquinone, coenzyme Q <sub>10</sub> or Q <sub>10</sub>

FF, functional food; DS, dietary supplement; MeSH, Medical Subject Heading.

the publications found. Two authors of this report (S. E. and C. R.) independently reviewed the methodological quality of the included trials using the Jadad scoring system to evaluate the effect of study quality on the observed results. This validated scoring system assigns points for randomisation, double-blinding, and documentation of patient withdrawal, as well as additional points for the appropriateness of the randomisation and blinding methods<sup>(12)</sup>. Trials scoring 3 points or above, out of a maximum of 5, are generally considered to be of good methodological quality. Discrepancies between the two authors were settled through discussion.

In the following section we will first explain our current understanding of the mechanism of action by which the FF or DS may support statin treatment. Subsequently, the effects of the FF or DS in the healthy population and approved health claims will be discussed and we will summarise the results of clinical and observational studies exploring the combination therapy. Finally, safety aspects of the combination are addressed.

### Plant sterols and stanols

#### *Mechanism of supporting statin therapy*

Plant sterols and stanols lower serum levels of total cholesterol and LDL-cholesterol through a different mechanism compared with statins. Whereas statins inhibit hepatic cholesterol synthesis, plant sterols and stanols reduce the intestinal absorption of cholesterol. Therefore it is thought that both mechanisms work simultaneously when statins and plant sterols and/or stanols are taken together. It is generally assumed that plant sterols and stanols compete with both dietary and biliary cholesterol for solubilisation into mixed micelles. Because plant sterols and stanols are more hydrophobic than cholesterol, they have a higher affinity for the micelle<sup>(13,14)</sup>. Other mechanisms proposed are the interference with the cholesteryl ester-mediated hydrolysis process necessary for absorption, and/or stimulation of the ATP-binding cassette (ABC) transporter expression by plant sterols and stanols<sup>(13,15–17)</sup>. The ABCG5 and ABCG8 transporters actively transport dietary sterol out of the enterocytes back into the intestinal lumen, thereby limiting the amount of sterol absorbed. ABCA1 may also participate in this process<sup>(18)</sup>. However, studies in plant sterol- and stanol-treated ABCA1- and ABCG5/G8-deficient mice have not demonstrated the


involvement of these ABC transporters in the reduction of intestinal cholesterol absorption<sup>(19)</sup>. Differences in *ABCG5* and *ABCG8* genes between humans and murines might (partly) explain these results<sup>(20)</sup>.

Decreased cholesterol absorption is associated with a compensatory increase in cholesterol synthesis and an increase in LDL receptor expression. This elevated expression may not only lead to an increased clearance of LDL from the circulation, but also of intermediate-density lipoprotein (IDL). Because IDL is the precursor of LDL-cholesterol, this may ultimately lead to a decreased LDL production. The net

result of the lower cholesterol absorption, higher LDL expression and higher endogenous cholesterol synthesis is a reduction in serum total and LDL-cholesterol concentration<sup>(13,17)</sup> (Fig. 1).

#### *Estimated effects of plant sterols and stanols on lipid levels and health claims*

Plant sterol and stanol esters have been incorporated in dairy products such as low-fat margarine, milk and yoghurt. Also cereals, bread and orange juice containing esterified or non-



**Fig. 1.** Postulated cholesterol-lowering mechanisms of statins, plant sterols and stanols and soluble dietary fibre. Statins inhibit the enzyme hydroxymethylglutaryl CoA (HMG-CoA) reductase (1). Plant sterols and stanols compete with cholesterol for solubilisation into mixed micelles (2), leading to a reduced luminal absorption of cholesterol and/or they induce a higher expression of the ATP-binding cassette (ABC) transporter (3), resulting in an efflux of cholesterol back into the intestinal lumen. Both mechanisms lead to an increased faecal output (4)<sup>(13,17)</sup>. Soluble dietary fibre interrupts with cholesterol and/or bile acid (re)absorption (5), either by binding bile acids or by forming a thick unstirred water layer in the intestinal lumen, leading to an increased faecal output (4). Compensatory up-regulation of the enzyme cholesterol 7- $\alpha$ -hydroxylase (6) increases the conversion of cholesterol into bile acids. All processes will result in a reduction in the cholesterol content of liver cells what will lead to an up-regulation of LDL receptors (LDLr) and ultimately in an increased clearance of circulation LDL-cholesterol (LDLc) (7)<sup>(59,66,68)</sup>.

esterified plant sterols or stanols are available on the market. Since 2001, the Adult Treatment Panel of the US National Cholesterol Education Program has recommended the use of plant sterols or stanols (2 g/d) in conjunction with other lifestyle changes to enhance LDL-cholesterol reduction. The panel states that daily intake of 2–3 g plant sterol or stanol esters will reduce LDL-cholesterol by 6–15 %<sup>(5)</sup>. Plant sterols and stanols do not have an effect on TAG or HDL-cholesterol levels<sup>(21,22)</sup>. However, two recent meta-analyses evaluated the LDL-cholesterol-lowering effects of plant sterols and/or stanols. Both found that LDL-cholesterol reduction was approximately 0.33 mmol/l for a mean daily intake of 2.1–2.5 g plant sterols and/or stanols<sup>(23,24)</sup>.

Plant sterols and stanols have approved health claims in the USA and in Europe. According to the United States Food and Drug Administration (FDA) there is significant scientific agreement for a consistent, clinically significant effect of plant sterols and stanols on blood total and LDL-cholesterol in both mildly and moderately hypercholesterolaemic (HC) populations. Therefore it has authorised the use of health claims on the association between plant sterol and stanol esters and reduced risk of CHD on food labels. The claims states that 'Diets low in saturated fat and cholesterol that include two servings of foods that provide a daily total of at least 1.3 g of plant sterol esters or 3.4 g of plant stanol esters, may reduce the risk of heart disease'<sup>(25,26)</sup>. Based on the scientific evidence available at the time of evaluation, the FDA made a distinction between the amount of plant sterols and plant stanols necessary to lower total and LDL-cholesterol. However, in a clinical trial comparing the cholesterol-lowering efficacy of plant sterols and plant stanols, published shortly after the claim authorisation, no significant difference between esterified plant sterols and plant stanols was found<sup>(27)</sup>.

Since January 2007, Regulation 1924/2006 applies to nutrition and health claims made in commercial communications in all European Union countries<sup>(28)</sup>. The European Food Safety Authority (EFSA) was requested to evaluate scientific data on plant sterols and stanols in accordance with the Regulation and approved in 2008 health claims stating: 'Plant sterols and plant stanol esters have been shown to lower/reduce blood cholesterol. Blood cholesterol lowering may reduce the risk of coronary heart disease'<sup>(29,30)</sup>. This advice has been provided to the European Commission and member states who will adopt and authorise the health claims<sup>(31)</sup>.

As concerns safety, the Scientific Committee on Food has assessed plant sterol-enriched foods under the novel foods procedure (European Union Regulation 258/97)<sup>(32)</sup>. They concluded that a maximum level of 8 % non-esterified plant sterols, consisting of 30–65 %  $\beta$ -sitosterol, 10–40 % campesterol, 6–30 % stigmasterol and a total of 5 % other plant sterols, is safe for human use, also stating that patients on cholesterol-lowering medication should only consume the enriched products under medical supervision<sup>(33)</sup>. Plant stanols were not assessed through the novel foods procedure as these products were consumed in Finland already before 1997<sup>(34)</sup>.

#### *Effects of combination therapy with plant sterols and/or stanols and statins*

Vanhanen<sup>(35)</sup> was the first to conduct a clinical trial towards the effects of sitostanol esters on lipid levels in patients on

pravastatin treatment. It was found that the daily addition of 1.5 g sitostanol ester did not lower serum total or LDL-cholesterol after 6 weeks of supplementation. In contrast, subsequent studies, using higher doses, all reported that plant sterols or stanols in combination with various statins have additive effects on total and LDL-cholesterol reduction in patients with (familial) hypercholesterolaemia (FH), as summarised in Tables 2–4.

In Table 2, results of clinical studies are presented that investigated the effects of adding plant sterols or stanols, either in tablet form or incorporated into food products, on lipid levels in patients on (stable) statin treatment. In seven studies, using doses of plant sterols or stanols varying from 1.8 g/d to 6.0 g/d and with intervention periods between 4 and 16 weeks, effects were found ranging from a 6 to 10 % decrease for total cholesterol and from a 6 to 15 % decrease for LDL-cholesterol. Absolute reductions in total and LDL-cholesterol ranged from 0.31 to 0.62 mmol/l and from 0.30 to 0.67 mmol/l, respectively. The largest reductions were found in a cross-over trial conducted in patients with FH<sup>(36)</sup>, although these reductions are probably partly caused by the low-fat spread as the results were not corrected for changes in a placebo-controlled group and no run-in period on placebo spread was used.

The results for total cholesterol were statistically significant for five out of seven studies<sup>(36–40)</sup>, and either borderline significant ( $P=0.052$ )<sup>(41)</sup> or non-significant<sup>(42)</sup> for the two remaining studies. Reductions in LDL-cholesterol were not significantly different between the intervention and control group only in a single-blind study performed by Castro Cabezas *et al.*<sup>(42)</sup>. This may have been due to the significant reduction in LDL-cholesterol in both the intervention and the control group, caused by the nutritional guidelines and low-fat margarines given to both groups, which may have made it more difficult to find significant differences in reductions between the two groups. The methodological quality of this clinical trial was poor based on components assessed by the Jadad scale. The majority of the studies did not find any significant effects of plant sterols or stanols on HDL-cholesterol or TAG, nor were the effects of plant sterols different compared with the effects of plant stanols. However, Ketomaki *et al.* found in a study consisting of two consecutive 4-week intervention periods with either a plant stanol ester or a plant sterol ester that only during the sterol ester period HDL-cholesterol increased and TAG levels decreased significantly<sup>(36)</sup>. This study achieved a Jadad score of 3; no placebo-controlled group was included in this study, possibly leading to flawed results.

Table 3 shows the results of studies investigating the differences in effects that plant sterols or stanols have on lipid levels in statin users and non-statin users. All studies have demonstrated that if plant sterols or stanols are added to a statin, the effect on cholesterol reduction is similar<sup>(40,43)</sup> or even higher<sup>(44)</sup> compared with that observed with the use of the plant sterols or stanols alone.

De Jong *et al.*<sup>(45)</sup> and Wolfs *et al.*<sup>(46)</sup> also investigated the cholesterol-lowering effects of plant sterol- and stanol-enriched margarine (no differentiation between plant sterols and stanols) between statin users and non-statin users in a post-marketing surveillance setting over 5 years. These authors suggest that plant sterols and stanols have an additive

**Table 2.** Clinical studies towards the effects on lipid levels (total, LDL- and HDL-cholesterol and TAG) of the combination therapy with statins and plant sterols or stanols: effects of plant sterols or stanols in statin users

Author	Type of study	Jadad score	Subjects	Plant sterol or stanol/ control intervention	Study duration	Net change in lipid levels‡			
						Total cholesterol	LDL	HDL	TAG
Vanhanen (1994) <sup>(35)</sup>	DB, PC, R	3	HC on pravastatin therapy ≥ 1 year (n 14)	1.5 g sitostanol ester per d in mayonnaise (n 7)/P: rapeseed oil-based mayonnaise (n 7)	6 weeks	-0.17 mmol/l	-0.07 mmol/l	NS	NS
Richter (1996) <sup>(39)</sup>	R, OL	1	HC on lovastatin therapy for 16 weeks (n 30)	6.0 g β-sitosterol per d in tablets (n 15)/- (n 15)	12 weeks	-7.4 % (-0.54 mmol/l)*	-10.3 % (-0.55 mmol/l)*	NS	NS
Blair <i>et al.</i> (2000) <sup>(37)</sup>	DB, PC, R	4	HC on stable statin therapy ≥ 3 months (n 167)	5.1 g plant stanol ester per d in spread (n 83)/P: rapeseed oil-based spread (n 84)	8 weeks	-6.9 % (-0.41 mmol/l)***	-10.0 % (-0.36 mmol/l)***	NS	NS
Simons (2002) <sup>(40)</sup>	DB, PC, R	4	HC (n 75)§	Cerivastatin + 2 g plant sterol ester per d in spread (n 37)/cerivastatin + P: regular spread (n 38)	4 weeks	-5.7 %*	-6.1 %*	NS	NS
Ketomaki <i>et al.</i> (2005) <sup>(36)</sup>	DB, R, AC, CO	3	FH on stable statin therapy ≥ 2 months (n 18)	2 g plant stanol ester per d and 2 g plant sterol ester per d in spread, CO (n 18)	4 weeks, 4 weeks (CO)	-9.8 % (-0.62 mmol/l)*	-14.8 % (-0.67 mmol/l)*	Stanol: NS  Sterol: +8.7 % (+0.11 mmol/l)**	Stanol: NS  Sterol: -11.8 % (-0.14 mmol/l)**
Castro Cabezas <i>et al.</i> (2006) <sup>(42)</sup>	SB, PC, R	1	HC on stable statin therapy ≥ 6 months (n 20)	3 g plant stanol ester per d in spread (n 11)/P: regular spread (n 9)	6 weeks	-6.6 % (-0.40 mmol/l)	-7.9 % (-0.30 mmol/l)	NS	NS
Goldberg <i>et al.</i> (2006) <sup>(38)</sup>	DB, PC, R	4	HC on stable statin therapy ≥ 3 months (n 26)	1.8 g soya stanol per d in tablets (n 13)/P: starch-containing tablets (n 13)	6 weeks	-5.7 % (-0.31 mmol/l)*	-9.1 % (-0.32 mmol/l)**	NS	NS
De Jong <i>et al.</i> (2007) <sup>(41)</sup>	DB, PC, R	4	HC on statin therapy (n 41)	2.5 g plant stanol (n 15) or sterol ester per d in spread (n 15)/P: 'light' spread (n 11)	16 weeks	-6.9 % (-0.39 mmol/l)†	-10.3 % (-0.34 mmol/l)*	NS	NS

DB, double-blind; PC, placebo-controlled; R, randomised; HC, hypercholesterolaemic; P, placebo; OL, open-label; AC, active controlled; CO, cross-over; FH, familial hypercholesterolaemia; SB, single-blind.

\*  $P < 0.05$ , \*\*  $P < 0.01$ , \*\*\*  $P < 0.001$ .

† Borderline significant.

‡ The net change in lipid levels was calculated by subtracting the mean change from baseline after control intervention from the mean change from baseline after plant sterol or stanol intervention, except for the study of Ketomaki *et al.*<sup>(36)</sup> where the net change is the mean change from baseline after plant sterol and stanol intervention.

§ The study of Simons<sup>(40)</sup> is a 2 × 2 factorial design study with four parallel arms. In this table the net change is calculated by subtracting the mean change from baseline after statin intervention from the mean change from baseline after combined intervention of plant sterols and statins.

|| No significant difference between sterol and stanol esters.

**Table 3.** Clinical studies towards the effects on lipid levels (total, LDL- and HDL-cholesterol and TAG) of the combination therapy with statins and plant sterols or stanols: difference in effects of plant sterols or stanols between statin users and non-statin users

Author	Type of study	Jadad score	Subjects		Plant sterol or stanol/control intervention	Study duration	Net change in lipid levels†			
			Statin therapy	No statin therapy			Total cholesterol	LDL	HDL	TAG
Gylling <i>et al.</i> (1997) <sup>(43)</sup>	DB, R	2	CHD females on simvastatin therapy ≥ 1 year (n 10)	CHD females (n 11)	3 g sitostanol ester per d in rapeseed oil-based spread (n 21)	7 weeks, 12 weeks‡	+1.7% (+0.24 mmol/l)§	+2.4% (+0.23 mmol/l)§	NS	NS
Vuorio <i>et al.</i> (2000) <sup>(44)</sup>	OL	1	FH on simvastatin therapy ≥ 90 d (n 12)	FH (n 4)	2.2g stanol ester per d in rapeseed oil-based spread (n 16)	6 weeks, 12 weeks‡	-3.1% (+0.18 mmol/l)**§	-8.5% (+0.08 mmol/l)**§	NS	NS
Simons (2002) <sup>(40)</sup>	DB, PC, R	4	HC (n 76)‡	HC (n 76)‡	Cerivastatin + 2g plant sterol ester per d in spread (n 37)/2g plant sterol ester per d in spread + P; placebo drug (n 39)	4 weeks	+1.8%	+4.1%	NS	NS

DB, double-blind; R, randomised; CHD, patients with coronary artery disease; OL, open-label; FH, familial hypercholesterolaemia; PC, placebo-controlled; HC, hypercholesterolaemic; P, placebo.

\*\* P < 0.01, \*\*\* P < 0.001.

† The net change in lipid levels was calculated by subtracting the mean change from baseline after plant sterol or stanol intervention in the non-statin users from the mean change from baseline after plant sterol or stanol intervention in the statin users.

‡ The study of Simons<sup>(40)</sup> is a 2 × 2 factorial design study with four parallel arms. In this table the net change is calculated by subtracting the mean change from baseline after plant sterol intervention in patients on placebo drug from the mean change from baseline after plant sterol intervention in patients on cerivastatin.

§ In both groups significant reduction.

|| Simvastatin-treated patients 7 weeks, not treated patients 12 weeks.

¶ Simvastatin-treated patients 6 weeks, not treated patients 12 weeks.

effect to the drug, although significance levels were not reached because of the small number of combination users in the studies. Moreover, Simons<sup>(40)</sup> performed a 2 × 2 factorial study with four parallel treatment arms, aiming to distinguish between an additive effect and an interactive effect between plant sterol ester margarine and cerivastatin. Statistical analysis showed no evidence of an interactive effect and therefore the authors concluded that, although a small interaction between the two compounds could not be excluded, it is unlikely that this interaction is of any clinical importance.

In Table 4, the pooled results are given of studies not differentiating between statin users and non-statin users. Moreover, statin use was not quantified and cholesterol-lowering effects of plant sterols and stanols in normal, HC or FH patients were put together. All studies described significant reductions in total and LDL-cholesterol levels and suggested that the plant sterols and stanols were effective in both statin users as well as non-statin users<sup>(47–49)</sup>.

In summary it can be concluded that plant sterol and plant stanol esters are an effective approach to lower cholesterol levels in addition to statin treatment in both HC and FH patients on statin treatment. Cholesterol lowering is at least equally effective in statin users compared with non-users. The addition of 2–5 g plant sterol or stanol esters per d to statins will result in an additive LDL- and total cholesterol reduction of roughly 10 (or 0.40 mmol/l) and 6% (or 0.35 mmol/l) respectively, without significant changes in HDL-cholesterol or TAG levels. Effects in FH patients might even be slightly greater, although well-designed randomised double-blind trials are needed to confirm this hypothesis.

Differences in cholesterol-lowering effects of plant sterols or stanols between the different studies might be explained by baseline cholesterol levels, because it has been hypothesised that patients with high baseline cholesterol levels experience a larger reduction in cholesterol levels after sterol or stanol ester consumption<sup>(36)</sup>. Moreover, it is suggested that patients with high ratios of serum cholestanol and plant sterols to cholesterol (markers for cholesterol absorption) may benefit the most from plant stanol or sterol intake<sup>(50)</sup>. A synergistic effect between statins and plant sterols and/or stanols should not be expected<sup>(51)</sup>.

#### Safety aspects of combination therapy with plant sterols and/or stanols and statins

In none of the studies were adverse effects related to the use of plant sterol- or stanol-enriched products in combination with statin therapy found. However, in studies towards the effects of plant sterols alone, it has been found that serum plant sterol concentration is elevated after consumption of plant sterols (unlike plant stanols) with potential atherogenic effects<sup>(52)</sup>. Normally, only 5–15% of the plant sterols are absorbed in the intestinal tract<sup>(51,53)</sup>. Patients with the rare autosomal recessive disease phytosterolaemia, however, are hyperabsorbers of plant sterols and should therefore not consume products containing high amounts of plant sterols, whether added to statin therapy or not. In healthy subjects, it is assumed that the beneficial effects on cholesterol levels of plant sterols outweigh any potential atherosclerotic risk, although additional research on this topic is urgently warranted<sup>(54,55)</sup>.

**Table 4.** Clinical studies towards the effects on lipid levels (total, LDL- and HDL-cholesterol and TAG) of the combination therapy with statins and plant sterols or stanols: effects of plant sterols or stanols in combined groups of statin users and non-statin users

Author	Type of study	Jadad score	Subjects		Plant sterol or stanol/control intervention	Study duration	Net change in lipid level†			
			Statin therapy	No statin therapy			Total cholesterol	LDL	HDL	TAG
Neil <i>et al.</i> (2001) <sup>(48)</sup>	DB, PC, R	5	FH on statin therapy (n 30)	HC (n 32)	2.5 g plant sterol per d in spread (n 31)/P: mixed oil-based spread (n 31)	8 weeks	-7.8% (-0.57 mmol/l)**	-10.0% (-0.51 mmol/l)***	NS	NS
Amundsen <i>et al.</i> (2004) <sup>(47)</sup>	OL	1	FH on statin therapy (n 19)	FH (n 1)	1.5 g plant sterol ester per d in spread (n 20)	26 weeks	-9.1%	-11.0% (-0.45 mmol/l)*	-10.6% (-0.13 mmol/l)***	NS
O'Neill <i>et al.</i> (2004) <sup>(49)</sup>	DB, PC, R	4	FH on statin therapy (n 69)	Unaffected (n 65)	2.6 g plant stanol ester per d in spread and bar (n 46)/1.6 g plant sterol ester per d in spread + P: regular bar (n 42)	8 weeks	-8.5% (-0.5 mmol/l)**‡	-8.1% (-0.31 mmol/l)‡	NS	NS

DB, double-blind; PC, placebo-controlled; R, randomised; FH, familial hypercholesterolaemia; HC, hypercholesterolaemic; P, placebo; OL, open-label.

\*  $P < 0.05$ , \*\*  $P < 0.01$ , \*\*\*  $P < 0.001$ .

† The net change in lipid levels was calculated by subtracting the mean change from baseline after control intervention from the mean change from baseline after plant sterol or stanol intervention in a combined group of statin users and non-statin users, except for the studies of Amundsen *et al.*<sup>(47)</sup> and O'Neill *et al.*<sup>(49)</sup> where the net change is the mean change from baseline after plant sterol or stanol intervention.

‡ No significant difference between sterol or stanol ester or between high- and low-dose stanol.

Furthermore, both plant sterols and stanols are associated with reductions in plasma concentrations of  $\alpha$ -carotene,  $\beta$ -carotene, lycopene and  $\alpha$ -tocopherol. Reductions in all vitamins, except for  $\beta$ -carotene, can be explained by reductions in LDL-cholesterol, the main lipoprotein carrier. Negative health effects related to these reductions are not expected<sup>(51)</sup>, although it might be a concern for groups with high nutritional needs such as elderly and pregnant women. These groups can be advised to add an extra amount of fruits and vegetables to the diet.

In addition, post-marketing surveillance of plant sterols and stanols upon request of the European Commission did not indicate adverse effects<sup>(56)</sup>, thereby supporting the safety of these products<sup>(33)</sup>.

## Soluble dietary fibre

### *Mechanism of supporting statin therapy*

Dietary fibres are associated with a reduced risk of CHD. Soluble fibre appears to be primarily responsible for the cholesterol-lowering effect of dietary fibre intake<sup>(57)</sup>. Studies in HC patients without treatment with cardiovascular drugs showed that addition of soluble fibres (psyllium<sup>(58,59)</sup>,  $\beta$ -glucan<sup>(60–63)</sup>, guar gum<sup>(64,65)</sup>, pectin<sup>(66)</sup>) to a low-fat, low-cholesterol diet was an effective approach to reduce total and LDL-cholesterol. The mechanisms involved are not completely understood, but it is suggested that soluble fibres reduce plasma cholesterol by interruption with cholesterol and/or bile acid (re)absorption<sup>(67)</sup>. Some authors suggest that soluble fibres bind bile acids; others assume that water-soluble fibres form a thick unstirred water layer in the intestinal lumen. Both proposed mechanisms will lead to an increased faecal output of bile acids, resulting in a reduction in bile acids available for transport back to the liver. Compensatory up-regulation of hepatic enzymes such as cholesterol 7- $\alpha$ -hydroxylase, the rate-limiting enzyme in bile acid biosynthesis, results in a reduction in the cholesterol content of liver cells. This leads to an up-regulation of the LDL receptors and the enzyme HMG-CoA reductase to re-establish hepatic cholesterol stores, ultimately resulting in an increased clearance of circulating LDL-cholesterol<sup>(59,66,68)</sup> (Fig. 1). Other suggested mechanisms include the inhibition of cholesterol synthesis by SCFA (mainly propionate), which are the major fermentation products of soluble fibre, the increased intestinal viscosity causing lowered glucose absorption and thereby improving insulin sensitivity, and the increased satiety leading to lower overall energy intake<sup>(66,68)</sup>. These postulated mechanisms differ from the cholesterol-lowering mechanism of statins, and therefore both compounds may decrease cholesterol levels simultaneously.

### *Estimated effects of soluble dietary fibre on lipid levels and health claims*

In a meta-analysis, it was estimated that 2–10 g soluble fibre per d significantly lowers total and LDL-cholesterol concentrations by 0.045 and 0.057 mmol/l, respectively<sup>(66)</sup>. Various soluble fibres, including oat products, psyllium, pectin and guar gum, reduce total and LDL-cholesterol by similar amounts; the effects depend on the food matrix used,

the method of food processing and the concentration, water-solubility and molecular weight of the fibres.

In 1997 the FDA adopted health claims on the labels of foods containing  $\beta$ -glucan soluble fibre of whole oats noting that these foods, as part of a diet low in saturated fat and cholesterol, may reduce the risk of heart disease by reducing total and LDL-cholesterol. Since then, this claim was extended by adding psyllium seed husk, whole-grain barley products and barley  $\beta$ -fibre as additional eligible sources of soluble fibre. The FDA states that the food products must provide at least 0.75 g of  $\beta$ -glucan soluble fibre or 1.7 g of psyllium soluble fibre per serving<sup>(69,70)</sup>.

In Europe, member states such as Sweden, The Netherlands and UK have also approved claims linking oat soluble fibre consumption and reduced total and LDL-cholesterol<sup>(71–73)</sup>. This has led to the introduction of several food products enriched with soluble fibre, including bread, cereals and cookies. However, in the context of Regulation 1924/2006, the claims currently used in the different member states need to be reviewed by the EFSA<sup>(28)</sup>.

*Effects of combination therapy with soluble dietary fibre and statins*

Results of studies exploring the combination therapy with soluble dietary fibre and statins are shown in Tables 5 and 6. All studies scored less than 4 points on the Jadad scale.

Table 5 shows the effects on lipid levels of soluble fibre in statin users. One of the first studies performed towards this combination found that in three female HC patients, the addition of pectin daily to treatment with lovastatin resulted in an average rise in LDL-cholesterol of 42%. After the intake of pectin was stopped, levels returned to normal. Also after the addition of oat bran to lovastatin the LDL-cholesterol levels rose strikingly in two patients in the same study. The authors concluded that both fibres might reduce the bioavailability of the statin<sup>(74)</sup>. Further studies towards this specific combination have not been performed, but Uusitupa *et al.* studied the effects of guar gum in a population of both FH and non-FH patients on lovastatin treatment and reported that adding guar gum resulted in significant reductions in serum total and LDL-cholesterol. However, the results might be flawed because no placebo group was included and no correction for food intake was made<sup>(75,76)</sup>.

Table 6 presents the results of three studies comparing the effects on lipid values of the combination therapy of a statin and soluble dietary fibre *v.* statin treatment alone. Whereas total and LDL-cholesterol-lowering effects of the soluble fibres reached statistical significance in the studies performed by Moreya *et al.*<sup>(77)</sup> and Jayaram *et al.*<sup>(78)</sup>, only trends towards an additive effect were observed by Agrawal *et al.*<sup>(79)</sup>. It should be noted that this last trial was conducted in healthy adult men, and therefore results may differ from effects observed in the other studies performed in HC patients. Of note is that in two out of the three studies a blunting of the statin-associated increase in HDL-cholesterol was observed after addition of the soluble dietary fibre<sup>(77,79)</sup>.

In conclusion we can say that studies towards the possible beneficial effects of soluble dietary fibre on statin therapy are scarce. Most clinical studies have reported negative associations between the use of soluble fibre supplements in

**Table 5.** Clinical studies towards the effects on lipid levels (total, LDL- and HDL-cholesterol and TAG) of the combination therapy with statins and soluble dietary fibre: effects of soluble dietary fibre in statin users

Author	Type of study	Jadad score	Subjects	Soluble dietary fibre	Study duration	Net change in lipid level†				
						Total cholesterol	LDL	HDL	TAG	
Richter <i>et al.</i> (1991) <sup>(74)</sup>	OL	–‡	HC females (n 3) on lovastatin therapy	Pectin 15 g/d (n 3)	4 weeks	NM	+42%	NM	NM	NM
Uusitupa <i>et al.</i> (1991) <sup>(75)</sup>	OL	1	HC (n 31) on lovastatin therapy (80 mg/d) for 18 weeks	Guar gum tablets 5–20 g/d (n 31)	18 weeks	–14% (–1.0 mmol/l)***	–18% (–0.9 mmol/l)***	NS	–7.7% (–0.1 mmol/l)	

OL, open-label; HC, hypercholesterolaemic; NM, not measured or calculated.

\*\*\*  $P < 0.001$ .

† The net change in lipid levels is the mean change from baseline after soluble dietary fibre intervention.

‡ Jadad score was not estimated because description of the study design has not been published (study was interrupted after three patients).



**Table 6.** Clinical studies towards the effects on lipid levels (total, LDL- and HDL-cholesterol and TAG) of the combination therapy with statins and soluble dietary fibre: difference in effects of a statin plus soluble dietary fibre v. a statin alone

Author	Type of study	Jadad score	Subjects	Soluble dietary fibre/control intervention	Study duration	Net change in lipid levels†				
						Total cholesterol	LDL	HDL	TAG	
Moreyra <i>et al.</i> (2005) <sup>(77)</sup>	DB, PC, R	3	HC (n 46)	Simvastatin (10 mg/d) + psyllium-powder drink (15 g/d) (n 23)/simvastatin (10 mg/d) + P (n 23)	8 weeks	-3.9% (-0.24 mmol/l)*	-5.1% (-0.21 mmol/l)*	-9.1% (-0.13 mmol/l)**	+8.7% (+0.07 mmol/l)	
Jayaram <i>et al.</i> (2007) <sup>(78)</sup>	OL, R	2	HC (n 97)	Atonvastatin (10 mg/d) + psyllium-powder drink (11.2 g/d) (n 49)/atorvastatin (10 mg/d) (n 48)	12 weeks	-4.4% (-0.28 mmol/l)	-8.6% (-0.35 mmol/l)*	-6.4% (-0.06 mmol/l)	+0.99% (+0.06 mmol/l)	
Agrawal <i>et al.</i> (2007) <sup>(79)</sup>	OL, R	3	Unaffected males (n 24)	Lovastatin (20 mg/d) + psyllium-powder drink (10 g/d) (n 12)/lovastatin (20 mg/d) (n 12)	4 weeks	-6.7% (-0.3 mmol/l)	-8.6% (-0.2 mmol/l)	-7.1% (-0.07 mmol/l)	+6.7% (+0.08 mmol/l)	

DB, double-blind; PC, placebo-controlled; R, randomised; HC, hypercholesterolaemic; P, placebo; OL, open-label.

\*  $P < 0.05$ , \*\*  $P < 0.01$ .

† The net change in lipid levels was calculated by subtracting the mean change from baseline after control intervention from the mean change from baseline after soluble dietary fibre intervention.

combination with statins and LDL- or total cholesterol concentrations. However, also unfavourable reductions in statin bioavailability and reductions in HDL-cholesterol have been described after high intake of soluble fibre. At this moment, there is not sufficient evidence to recommend the use of FF or DS enriched with soluble fibres in patients using statins. Clinical studies are warranted to further elucidate the potentials of the combination therapy with soluble dietary fibre and statins. Research should focus on the effects of different sources of soluble fibre in combination with various statins on lipoprotein subclasses and drug bioavailability. Caution should be taken to interpret the direct effects of fibre supplements instead of possible accompanying effects of reduced dietary fat and cholesterol intake. Also studies investigating the mechanisms of combined action and a possible dose-response relationship between combination therapy and cholesterol levels are needed.

#### *Safety aspects of combination therapy with soluble dietary fibre and statins*

Soluble fibre supplementation is generally considered as well tolerated. Side effects observed are mostly related to the gastrointestinal tract, such as abdominal distention, flatulence and diarrhoea. Also some negative nutritional impacts of high soluble fibre intake have been reported, as soluble fibres may interact with vitamins and minerals, resulting in a lower bioavailability of these compounds. However, there are insufficient data to firmly draw conclusions about this matter. Most likely, the effect of the fibre depends on the type of mineral or vitamin, the intestinal transit time and the degree of bacterial fibre degradation in the gut<sup>(64,80,81)</sup>.

The combination therapy with soluble fibre and statins may also have some safety limits, while unfavourable reductions in HDL-cholesterol have been described and in one study reduced statin absorption from the gut was suggested after a high intake of soluble fibre<sup>(74)</sup>. Studies towards the effects of soluble fibres on the bioavailability of statins and other drugs are scarce and results depend greatly upon the type of drug and fibre. Also the time of drug administration in relation to food intake may influence the bioavailability of the drug. Soluble fibres may influence the bioavailability of statins and other drugs by direct binding or by altering luminal pH, gastric emptying, intestinal transit, mucosal absorption and metabolism of the drug<sup>(58,82)</sup>.

#### *n-3 PUFA*

##### *Mechanism of supporting statin therapy*

In recent years a lot of research has been performed towards the association between intake of *n-3* PUFA and reduction in CHD. *n-3* PUFA operate via several mechanisms. One of the most important is the favourable effect of *n-3* PUFA on VLDL-cholesterol and TAG levels; in a meta-analysis of seventeen population-based prospective studies it was estimated that after adjustment for other risk factors, a 1 mmol/l increase in serum TAG is associated with a 14% increase in CVD risk in men and 37% in women<sup>(83)</sup>. Statins efficiently reduce total and LDL-cholesterol, but have only limited TAG-lowering effects; thus a combined intake of *n-3* PUFA

and a statin might be beneficial in improving the lipid profile in patients with high TAG levels. The favourable decrease in TAG levels caused by *n*-3 PUFA is probably due to reduced hepatic VLDL and TAG synthesis and secretion, and enhanced TAG clearance from chylomicrons and VLDL particles. Reduced synthesis might be due to increased rates of mitochondrial and/or peroxisomal  $\beta$ -oxidation or a decreased expression of sterol regulatory element-binding protein-1c, a transcription factor involved in the regulation of fatty acid-synthesising enzymes. Both mechanisms will result in a reduction in the availability of the substrate, i.e. fatty acids. Increased clearance is possibly caused by increased lipoprotein lipase activity due to increased PPAR- $\gamma$  and/or PPAR- $\alpha$  gene expression. Activation of PPAR leads to increased fatty acid  $\beta$ -oxidation in the liver and skeletal muscle<sup>(84–86)</sup>.

Other mechanisms by which *n*-3 PUFA may lower the risk of CHD include reductions in platelet aggregation, blood viscosity and ischaemia and their anti-thrombotic, fibrinolytic and anti-inflammatory activities. Moreover, *n*-3 PUFA appear to play an important role in the prevention of arrhythmias<sup>(87,88)</sup>.

#### *Estimated effects of n-3 PUFA on lipid levels and health claims*

In a recent meta-analysis of twenty-one randomised controlled trials it was estimated that *n*-3 PUFA consumption resulted in significant changes in TAG of  $-0.31$  mmol/l, in HDL-cholesterol of  $+0.04$  mmol/l and in LDL-cholesterol of  $+0.16$  mmol/l. There was no effect on total cholesterol<sup>(89)</sup>. It has been suggested that the unfavourable increase in LDL-cholesterol is attributable to the increased conversion of VLDL to IDL and LDL, and the conversion of IDL to LDL after *n*-3 PUFA supplementation<sup>(90,91)</sup>.

In September 2004 the FDA announced a qualified health claim for the use of food products containing both EPA and DHA *n*-3 PUFA for FF and DS<sup>(92)</sup>. According to the FDA there is supportive, but not conclusive, scientific evidence that suggests a reduction in CHD as a result of eating food or supplements rich in *n*-3 PUFA. The FDA judges that *n*-3 PUFA generally reduce TAG and VLDL-cholesterol, and have no effect on total or HDL-cholesterol in both general and diseased populations. The EFSA has not yet evaluated health claims on *n*-3 PUFA and cardiovascular function.

#### *Effects of combination therapy with n-3 PUFA and statins*

Results of clinical studies that have investigated the combination therapy with *n*-3 PUFA and statins are summarised in Tables 7 and 8. Contacos *et al.* were the first to demonstrate a beneficial effect of the combination of *n*-3 PUFA and statin therapy in HC patients<sup>(93)</sup>. They found that in patients randomised to either pravastatin, *n*-3 PUFA or placebo for 6 weeks, an additional 12 weeks of combination therapy with *n*-3 PUFA and pravastatin further decreased plasma TAG and LDL-cholesterol by 33% ( $P<0.05$ ) and 26% ( $P<0.01$ ), respectively, in patients in the placebo group, whereas in patients already on pravastatin only TAG levels were non-significantly decreased by 33% and in patients in the *n*-3 PUFA group only LDL-cholesterol levels were decreased by 24% ( $P<0.05$ ). Total cholesterol levels

showed similar changes to LDL-cholesterol after combination therapy. This study indeed showed that statins particularly lowered total and LDL-cholesterol, whereas *n*-3 PUFA lowered TAG and not cholesterol levels. Combination therapy reduced both cholesterol and TAG concentrations. These beneficial effects of *n*-3 PUFA on TAG levels have been confirmed in later studies<sup>(94–104)</sup>.

Table 7 shows the results of studies examining the effects of supplementing patients on statin therapy with *n*-3 PUFA<sup>(93,97,98,100–103,105)</sup>. All studies used EPA and/or DHA, in doses varying from 0.9 to 1.8 g/d and 0.78 to 2.16 g/d for EPA and DHA, respectively. All studies found significant reductions in TAG, ranging from 16 (or 0.44 mmol/l) to 48% (or 1.2 mmol/l), after supplementing *n*-3 PUFA, except one study performed by Nordøy *et al.* in which no TAG-lowering effect was attributable to the *n*-3 PUFA<sup>(105)</sup>. In this study relatively low doses of *n*-3 PUFA (0.9 g/d EPA, 0.78 g/d DHA) were used, which could explain these results. However, one small, uncontrolled study (Jadad score = 0) in which twelve patients were supplemented with 0.9 g EPA per d and two patients with 1.8 g EPA per d showed highly significant reductions in TAG. In addition, in this study it was found that total cholesterol levels were significantly reduced and HDL-cholesterol was significantly increased after EPA supplementation<sup>(102)</sup>. Most studies performed in patients on statin therapy did not find any significant changes in total, LDL- or HDL-cholesterol, although in some studies VLDL-cholesterol was decreased<sup>(93,98,101)</sup>. In the COMBOS (Combination of prescription Omega-3 with Simvastatin) study<sup>(97)</sup>, administration of *n*-3-acid ethyl esters plus simvastatin improved, besides TAG levels, also total, HDL- and VLDL-cholesterol to a greater extent than simvastatin alone. On the unfavourable side, a trend was observed towards a greater reduction in LDL-cholesterol in the simvastatin-only group (0.7 v.  $-2.8$ %;  $P=0.052$ ).

Table 8 shows the results of studies comparing the effects on lipid values of a combination therapy of a statin and *n*-3 PUFA v. statin treatment alone. Davidson *et al.*<sup>(96)</sup> found that after treating HC patients with *n*-3 PUFA and/or simvastatin for 12 weeks, the TAG responses were similar in the EPA/DHA-group ( $-25.3$ %) and the combined group ( $-28.8$ %), and borderline significantly lower in the simvastatin group ( $-18.5$ %), whereas decreases in non-HDL-cholesterol and increases in HDL-cholesterol were statistically significant only for the combined (non-HDL:  $-24.8$ %, HDL:  $+10.4$ %) and simvastatin group (non-HDL:  $-25.8$ %, HDL:  $+7.2$ %). All other studies found significant improvements of TAG with a combination therapy compared with the statin therapy alone<sup>(94,95,97,99,104)</sup>. Study populations included, besides HC patients, renal transplant patients with persistent hypercholesterolaemia<sup>(99)</sup> and insulin-resistant obese men with dyslipidaemia<sup>(95)</sup>. In this last study, also atorvastatin alone significantly decreased TAG levels. The authors suggest that the two compounds reduce TAG levels through different mechanisms. Whereas *n*-3 PUFA reduced the hepatic secretion of VLDL-apoB, atorvastatin enhanced the clearance of all apo B-containing lipoproteins, resulting in an additive effect<sup>(94,95)</sup>. Aligeti *et al.* performed a retrospective cohort study in which they compared the change in plasma TAG levels between patients taking fish oil as monotherapy and patients who added fish oil to their usual lipid-lowering

**Table 7.** Clinical studies towards the effects on lipid levels (total, LDL- and HDL-cholesterol and TAG) of the combination therapy with statins and *n*-3 PUFA: effects of *n*-3 PUFA in statin users

Author	Type of study	Jadad score	Subjects	<i>n</i> -3 PUFA/control intervention	Study duration	Net change in lipid levels‡			
						Total cholesterol	LDL	HDL	TAG
Contacos <i>et al.</i> (1993) <sup>(93)</sup>	OL	1	HC on pravastatin therapy for 6 weeks ( <i>n</i> 9)	3 g PUFA oil§ per d ( <i>n</i> 9)	12 weeks	− 5.0% (− 0.3 mmol/l)	+ 9.7% (+ 0.3 mmol/l)	+ 6.9% (+ 0.07 mmol/l)	− 33.0% (− 1.6 mmol/l)
Nordøy <i>et al.</i> (1998) <sup>(103)</sup>	DB, PC, R	4	HC on simvastatin for 5 or 10 weeks ( <i>n</i> 42)	4 g PUFA per d in capsules   ( <i>n</i> 22)/P: maize oil capsules ( <i>n</i> 20)	5 weeks	− 9.8% (− 0.55 mmol/l)†	NM	+ 11.3% (+ 0.13 mmol/l)	− 43.3% (− 1.2 mmol/l)**
Nakamura <i>et al.</i> (1999) <sup>(102)</sup>	OL	0	HC on various statins for 30 ± 6 months ( <i>n</i> 14)	0.9 – 1.8 g EPA per d in capsules ( <i>n</i> 14)	3 months	− 11% (− 0.61 mmol/l)*	NM	+ 8.9% (+ 0.11 mmol/l)*	− 48% (− 0.99 mmol/l)**
Durrington <i>et al.</i> (2001) <sup>(98)</sup>	DB, PC, R	4	CHD on stable statin therapy ≥ 3 months ( <i>n</i> 59)	4 g PUFA per d in capsules   ( <i>n</i> 30)/P: maize oil capsules ( <i>n</i> 29)	24 weeks	− 13.9% (− 0.8 mmol/l)	− 10.5% (− 0.4 mmol/l)	− 27.3% (− 0.3 mmol/l)	− 26.5% (− 1.2 mmol/l)**
Nordøy <i>et al.</i> (2001) <sup>(105)</sup>	DB, PC, R	4	HC on atorvastatin for ≥ 10 weeks ( <i>n</i> 42)	2 g PUFA per d in capsules   ( <i>n</i> 22)/P: maize oil capsules ( <i>n</i> 20)	5 weeks	+ 4.7% (+ 0.3 mmol/l)	+ 4.4% (+ 0.15 mmol/l)	+ 5.7% (+ 0.06 mmol/l)*	+ 6.0% (+ 0.22 mmol/l)
Hong <i>et al.</i> (2004) <sup>(100)</sup>	DB, PC, R	4	HC on simvastatin therapy for 6–12 weeks ( <i>n</i> 40)	3 g PUFA per d in capsules ( <i>n</i> 20)/P: rapeseed oil capsules ( <i>n</i> 20)	8 weeks	− 3.7% (− 0.19 mmol/l)	− 5.0% (− 0.12 mmol/l)	+ 5.0% (+ 0.05 mmol/l)	− 16% (− 0.59 mmol/l)**
Meyer <i>et al.</i> (2007) <sup>(101)</sup>	DB, PC, R	2	HC on stable statin therapy ≥ 3 months ( <i>n</i> 27)	2.16 g DHA oil per d ( <i>n</i> 13)/P: olive oil ( <i>n</i> 14)	3 weeks	− 8.3% (− 0.38 mmol/l)	− 10.0% (− 0.25 mmol/l)	− 9.9% (− 0.10 mmol/l)	− 17.2% (− 0.44 mmol/l)*
Davidson <i>et al.</i> (2007) <sup>(97)</sup>	DB, PC, R	5	HC on stable statin therapy ≥ 2 months ( <i>n</i> 254)	Simvastatin + 4 g PUFA per d in capsules   ( <i>n</i> 122)/simvastatin (40 mg/d) + P: vegetable oil capsules ( <i>n</i> 132)¶	8 weeks	− 3.2% (− 0.17 mmol/l)**	+ 5.3% (+ 0.09 mmol/l)†	+ 5.2% (+ 0.06 mmol/l)***	− 24.7% (− 0.78 mmol/l)***

OL, open-label; HC, hypercholesterolaemic; DB, double-blind; PC, placebo-controlled; R, randomised; P, placebo; NM, not measured or calculated; CHD, patients with coronary artery disease.

\*  $P < 0.05$ , \*\*  $P < 0.01$ , \*\*\*  $P < 0.001$ .

† Borderline significant.

‡ The net change in lipid levels was calculated by subtracting the mean change from baseline after control intervention from the mean change from baseline after *n*-3 PUFA intervention, except for the studies of Contacos *et al.*<sup>(93)</sup> and Nakamura *et al.*<sup>(102)</sup> where the net change is the mean change from baseline after *n*-3 intervention.

§ EPA 67%, DHA 33%.

|| EPA 45–48%, DHA 36–39%.

¶ At inclusion simvastatin replaced any previous statin.

**Table 8.** Clinical studies towards the effects on lipid levels (total, LDL- and HDL-cholesterol and TAG) of the combination therapy with statins and *n*-3 PUFA: difference in effects of a statin plus *n*-3 PUFA v. a statin alone

Author	Type of study	Jadad score	Subjects	<i>n</i> -3 PUFA/control intervention	Study duration	Net change in lipid levels†			
						Total cholesterol	LDL	HDL	TAG
Davidson <i>et al.</i> (1997) <sup>(96)</sup>	DB, PC, R	2	HC (n 19)	Simvastatin (10 mg/d) + 5 g PUFA per d in capsules§ (n 9)/simvastatin + P (n 10)	12 weeks	-0.36% (-0.11 mmol/l)	+1.0% (-0.10 mmol/l)†	+3.2% (+0.05 mmol/l)	-10.3% (-0.14 mmol/l)†
Grekas <i>et al.</i> (2001) <sup>(99)</sup>	OL	1	Renal transplant HC (n 24)	Pravastatin (20 mg/d) + 1 g PUFA oil per d (n 24)††	8 weeks	+8.3% (+0.67 mmol/l)	-0.09% (+0.05 mmol/l)	+4.3% (+0.05 mmol/l)	-14.6% (-0.26 mmol/l)**
Chan <i>et al.</i> (2002) <sup>(94)</sup>	DB, PC, R	2	IR obese males (n 24)	Atorvastatin + 4 g PUFA per d in capsules   (n 11)/atorvastatin + P: maize oil capsules (n 13)	6 weeks	-0.2% (-0.2 mmol/l)	+4.9% (+0.08 mmol/l)	+9.6% (+0.11 mmol/l)*	-13.7% (-0.3 mmol/l)***
Yokoyama <i>et al.</i> (2007) <sup>(104)</sup>	OL, R	3	HC (n 18 645)	Prava- or simvastatin + 1.8 g EPA per d in capsules (n 9326)/prava- or simvastatin (n 9319)	5 years	NS	NS	NS	-5.0%***

DB, double-blind; PC, placebo-controlled; R, randomised; HC, hypercholesterolaemic; P, placebo; OL, open-label; IR, insulin-resistant.

\*  $P < 0.05$ , \*\*  $P < 0.01$ , \*\*\*  $P < 0.001$ .

† Borderline significant.

‡ The net change in lipid levels was calculated by subtracting the mean change from baseline after control intervention from the mean change from baseline after *n*-3 PUFA intervention.

§ EPA 60%, DHA 40%.

|| EPA 45–48%, DHA 36–39%.

¶ Values are non-HDL-cholesterol.

†† All patients received the same therapeutic protocol consisting of 4 weeks of diet, 8 weeks of diet + statin, 4 weeks of diet + statin + PUFA.

drugs, including statins<sup>(106)</sup>. They found that adding fish oil to a statin alone or to multiple lipid-lowering drugs (combination of niacin, statin and/or fibrates) did not alter the TAG-lowering effects of fish oil and effects are therefore additive.

One study compared the effects of the combination therapy and statins as monotherapy on clinical endpoints and found in the combined group a statistically significant 19% relative reduction in major coronary events, particularly unstable angina and non-fatal coronary events. This applied in both patients taking statins for primary prevention as for secondary prevention<sup>(104)</sup>. Few studies have examined the effects of combined treatment of *n*-3 PUFA and statins in patients with FH. Sandset *et al.* found no additional effects of adding *n*-3 PUFA (4 g/d for 6 weeks) to simvastatin (40 mg/d) in a small uncontrolled study (*n* 13); TAG even tended to increase on additional *n*-3 PUFA<sup>(107)</sup>. Also in another small study (*n* 14) in FH patients on chronic simvastatin treatment, TAG were not significantly decreased after *n*-3 PUFA supplementation (5.1 g/d)<sup>(108)</sup>. Small sample sizes or the population under study may explain these results.

In conclusion we can say that all clinical studies conducted in HC patients suggest that after combined intake of *n*-3 PUFA and statins no diminution of the separate effects of the compounds is expected, but that they improve lipid levels simultaneously through different mechanisms. Whereas statins alone have little effect on TAG levels, adding *n*-3 PUFA to the statin regimen lowered TAG significantly in most of the studies. Higher doses of *n*-3 PUFA and higher baseline TAG levels appear to be associated with greater reductions. In some, but not all studies, HDL-cholesterol was significantly increased and VLDL-cholesterol was significantly decreased after supplementation with *n*-3 PUFA. None of the studies found a significant favourable effect of *n*-3 PUFA on LDL-cholesterol and in some studies LDL-cholesterol even tended to increase after *n*-3 PUFA supplementation, contributing to the hypothesis that *n*-3 PUFA increase the conversion of VLDL to LDL. Effects of combined treatment with *n*-3 PUFA and statins in FH patients are less clear and studies examining these effects in larger populations are warranted.


#### Safety aspects of combination therapy with *n*-3 PUFA and statins

In none of the studies were adverse effects seen after combination therapy of *n*-3 PUFA and statins other than the adverse effects caused by monotherapy of the compound. *n*-3 PUFA were usually well tolerated and serious events have not been observed. Potential adverse effects related to *n*-3 PUFA include an increased bleeding time because of interference with platelet function, gastrointestinal disturbances and increases in LDL-cholesterol<sup>(97,109–111)</sup>.

#### Coenzyme Q<sub>10</sub>

##### Mechanism of supporting statin therapy

Statins act by inhibiting the activity of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis that catalyses the conversion of HMG-CoA to mevalonate. Besides being an intermediate in cholesterol synthesis, mevalonate is also a precursor of CoQ<sub>10</sub>; statins thus lower CoQ<sub>10</sub>



**Fig. 2.** Proposed mechanism by which coenzyme Q<sub>10</sub> supplements may support statin therapy. Statins inhibit the enzyme hydroxymethylglutaryl CoA (HMG-CoA) reductase (1) in the mevalonate pathway. The same pathway is shared by coenzyme Q<sub>10</sub> and as a consequence coenzyme Q<sub>10</sub> synthesis is inhibited (2)<sup>(112,113)</sup>. Coenzyme Q<sub>10</sub> supplements may raise the levels of coenzyme Q<sub>10</sub> (3) in plasma and platelets.

levels<sup>(112,113)</sup> (Fig. 2). CoQ<sub>10</sub> is known for its enzymic role in the production of energy within human cells, so CoQ<sub>10</sub> deficiency may impair muscle energy metabolism and contribute to the development of myalgia, a frequently reported adverse effect of statin treatment<sup>(114)</sup>. Supplementation with CoQ<sub>10</sub> can raise the circulating levels of CoQ<sub>10</sub> and might therefore be efficient in alleviating myopathic symptoms.

#### Coenzyme Q<sub>10</sub> and health claims

Dietary supplements containing CoQ<sub>10</sub> have not been evaluated for safety and effectiveness and there are no approved health claims for the use of CoQ<sub>10</sub>, neither in the USA nor in Europe.

#### Effects of combination therapy with coenzyme Q<sub>10</sub> and statins

Although studies have repeatedly demonstrated reduced levels of plasma CoQ<sub>10</sub> with statin therapy<sup>(113,115–117)</sup> and restored levels after oral CoQ<sub>10</sub> supplementation<sup>(113,118)</sup>, large randomised controlled trials towards the impact of CoQ<sub>10</sub> supplementation on statin-induced myalgia in patients with hyperlipidaemia are lacking. Only two double-blind controlled clinical trials investigating this area have been performed. The first study, assigned a Jadad score of 2, was a pilot study in forty-four patients with self-reported myalgia. Patients were randomised to supplementation with 200 mg CoQ<sub>10</sub> per d or placebo in combination with an upward dose of simvastatin (starting dose of 10 or 20 mg/d up to 40 mg/d) for 12 weeks. Results showed no difference between the groups in severity of myalgia, in the number of patients tolerating the highest dose of simvastatin, or in the number of patients remaining on therapy<sup>(119)</sup>. The second study, assigned a Jadad score

of 4, was performed in thirty-two patients with myopathic symptoms taking varying doses of statins, and supplemented with CoQ<sub>10</sub> (100 mg/d) or vitamin E (400 IU/d) for 30 d<sup>(114)</sup>. This study showed a significant 40 and 38 % reduction in pain severity and pain interference with daily activities, respectively, in the group treated with CoQ<sub>10</sub>. Vitamin E did not affect pain severity or pain interference. In this study, the benefit of CoQ<sub>10</sub> supplementation on improving pain was not stratified by statin type or dose.

In a third trial towards the effects of CoQ<sub>10</sub> supplementation on statin-induced myopathic symptoms, statin therapy was discontinued upon initial visit in all patients and no control group was included, so it is not clear what role CoQ<sub>10</sub> had in decreasing the incidence of myalgia<sup>(120)</sup>.

In summary it can be concluded that although some trial evidence exists about the effectiveness of CoQ<sub>10</sub> supplementation on myopathic symptoms, it is too early to recommend its routine use in clinical practice. The only randomised controlled clinical trials investigating this area showed contrasting results and further well-performed clinical trials are needed to investigate whether CoQ<sub>10</sub> can be used to support statin therapy. Although several studies have shown that plasma CoQ<sub>10</sub> levels are decreased after statin therapy, existing evidence also suggests that skeletal muscle CoQ<sub>10</sub> levels are not affected or even increased after statins<sup>(113,115,116)</sup>.

Alternative explanations for the myotoxic adverse effects of statins include instability of skeletal muscle cells due to reduction in cholesterol content of the membranes and inhibited production of GTP-binding proteins involved in cell growth and apoptosis. Apoptosis is a critical mechanism in the remodelling and maintenance of tissue structure and inappropriate apoptosis can produce pathological conditions<sup>(121,122)</sup>. Some of the decrease in CoQ<sub>10</sub> can probably be explained by the reduction in LDL-cholesterol levels after statin therapy, since CoQ<sub>10</sub> is transported in the LDL particle<sup>(121)</sup>.

#### Safety aspects of combination therapy with coenzyme Q<sub>10</sub> and statins

CoQ<sub>10</sub> is widely recognised as safe with no reported toxicity<sup>(123)</sup>. It has been shown that CoQ<sub>10</sub> supplementation (100 mg/d) in HC patients treated with atorvastatin (10 mg/d) did not have an effect on statin-induced reductions in total or LDL-cholesterol, or TAG levels<sup>(124)</sup>.

#### Discussion

The main objective of this review was to present options for the support of drug therapy with FF or DS. We focused on the support of statin therapy with plant sterols and stanols, soluble fibre, *n*-3 PUFA or CoQ<sub>10</sub>, because many subjects are treated suboptimally with statins and there are indications supporting combined use with one of these FF or DS.

There is substantial evidence that adding plant sterols or stanols to statin therapy reduces total and LDL-cholesterol, and that adding *n*-3 PUFA to statins reduces plasma TAG. Both combination treatments are without any changes in HDL-cholesterol. Neither supplementation of plant sterols or stanols nor supplementation with *n*-3 PUFA had any known clinical significant side effects, although *n*-3 PUFA supplementation

tended to increase LDL-cholesterol and plant sterol and stanol supplementation is associated with a reduction of  $\beta$ -carotene. Also the potential atherogenicity of elevated serum plant sterol concentrations needs to be further investigated.

Information about the combination therapy with either soluble dietary fibres or CoQ<sub>10</sub> and statins is less clear. Soluble dietary fibre and statins may have additive effects on reducing total and LDL-cholesterol levels. However, also an antagonistic effect of soluble fibre supplementation on statin therapy might be expected due to a reduced drug bioavailability. Furthermore, soluble fibre supplementation has been associated with a blunting of the HDL-cholesterol-increasing effect of statins. CoQ<sub>10</sub> may counteract the adverse myalgic effect produced by statins, but further studies are needed to confirm this hypothesis. Despite the safety and low costs of CoQ<sub>10</sub>, thus far it should not be recommended as a routine supplement with statin therapy in clinical practice. In the present review we discussed the (limited) available literature on the effectiveness of CoQ<sub>10</sub> supplementation in reducing myopathic symptoms. Also other functional foods or dietary supplements might be helpful in reducing statin-induced side effects. Se supplementation has been suggested to reduce both statin-induced liver injury<sup>(125,126)</sup> and myotoxicity<sup>(126)</sup>, and L-carnitine might improve statin-associated myotoxicity<sup>(127)</sup>. However, current research is limited to cell-culture and animal experiments, and human studies should be performed to assess the potential protective effects of these compounds in man. In the present review we have limited our literature search to human studies.

In conclusion it can be stated that using FF or DS might be an effective and safe approach to support drug therapy, especially when drugs alone are insufficient to achieve desirable effects on risk factors or when drug use is associated with side effects. In our example, FF or DS fortified with plant sterols or stanols or *n*-3 PUFA are a good option for supporting statin therapy. However, every combination of a drug and a FF or DS has to be investigated separately to draw conclusions about the type of effect: additive, synergistic, antagonistic or no effect. In our example of statin therapy, it is possible that various statins have different effects when combined to FF or DS, as statins vary in intestinal absorption and bioavailability. Also studies towards the effects of genetic polymorphisms are warranted as indicated by, for example, the association between variants in *SLCO1B1* (*solute carrier organic anion transporter family, member 1B1*) and increased risk of statin-induced myopathy<sup>(128)</sup>, the association between *ABCA1* expression and cholesterol absorption after intake of plant stanols<sup>(16)</sup>, and the association between polymorphisms in the fatty acid desaturase (*FADS*) genes and fatty acid concentrations in plasma and erythrocyte membranes<sup>(129–131,132)</sup>.

More research is needed towards the effect that a FF or DS has on side effects caused by drugs, and whether side effects can be reduced by replacing some dose of the drugs with FF or DS, without altering the effects on risk factors. Post-marketing surveillance studies are required to assess the long-term safety of the combination therapies and the safety in specific risk groups; clinical trials do often not attain adequate power for evaluating rare events and interactions. Moreover, the effectiveness of the combination therapies under customary conditions should be addressed as adherence to drugs is known to be suboptimal<sup>(133,134)</sup> and recommended doses of FF and DS might not be consumed<sup>(45,46,135)</sup>.

## Acknowledgements

The present review was funded by a grant from the National Institute for Public Health and the Environment (RIVM).

It was written by S. E., with O. K., J. G., H. V., H. vK., H. vL. and C. R. all providing comments. All authors reviewed the contents of the paper, approved its contents and validated the accuracy of the data.

The division of Pharmacoepidemiology and Pharmacotherapy employing authors S. E. and O. K. received unrestricted funding for pharmacoepidemiological research from Glaxo-SmithKline, Novo Nordisk, the private–public funded Top Institute Pharma (www.tipharma.nl, includes co-funding from universities, government and industry), the Dutch Medicines Evaluation Board and the Dutch Ministry of Health.

J. G., H. V., H. vK., H. vL. and C. R. have no conflicts of interest to disclose.

## Note added to proof

Since the paper was accepted, the European Commission and member states have adopted and authorised the health claims for plant sterols and stanols<sup>(136)</sup>. The European Food Safety Authority (EFSA) has evaluated and approved health claims for oat and barley  $\beta$ -glucans<sup>(137)</sup>.

## References

1. Guinness Centre (2004) *Global Market Review of Functional Foods – Forecasts to 2010*. Dublin: Guinness Centre.
2. Crowley R & FitzGerald LH (2006) The impact of cGMP compliance on consumer confidence in dietary supplement products. *Toxicology* **221**, 9–16.
3. de Jong N, Klungel OH, Verhagen H, *et al.* (2007) Functional foods: the case for closer evaluation. *BMJ* **334**, 1037–1039.
4. Mantel-Teeuwisse AK, Verschuren WM, Klungel OH, *et al.* (2003) Undertreatment of hypercholesterolaemia: a population-based study. *Br J Clin Pharmacol* **55**, 389–397.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA* **285**, 2486–2497.
6. Jones PH, Davidson MH, Stein EA, *et al.* (2003) Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR\* Trial). *Am J Cardiol* **92**, 152–160.
7. McKenney JM, Jones PH, Adamczyk MA, *et al.* (2003) Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. *Curr Med Res Opin* **19**, 689–698.
8. Law MR, Wald NJ & Rudnicka AR (2003) Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. *BMJ* **326**, 1423.
9. Kiortsis DN, Filippatos TD, Mikhailidis DP, *et al.* (2007) Statin-associated adverse effects beyond muscle and liver toxicity. *Atherosclerosis* **195**, 7–16.
10. Fincke BG, Miller DR & Spiro A III (1998) The interaction of patient perception of overmedication with drug compliance and side effects. *J Gen Intern Med* **13**, 182–185.
11. Cannon CP (2008) Combination therapy in the management of mixed dyslipidaemia. *J Intern Med* **263**, 353–365.

12. Jadad AR, Moore RA, Carroll D, *et al.* (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Control Clin Trials* **17**, 1–12.
13. Plat J & Mensink RP (2005) Plant stanol and sterol esters in the control of blood cholesterol levels: mechanism and safety aspects. *Am J Cardiol* **96**, 15D–22D.
14. Marinangeli CP, Varady KA & Jones PJ (2006) Plant sterols combined with exercise for the treatment of hypercholesterolemia: overview of independent and synergistic mechanisms of action. *J Nutr Biochem* **17**, 217–224.
15. Trautwein EA (2003) Proposed mechanisms of cholesterol-lowering action of plant sterols. *Eur J Lipid Sci Technol* **105**, 171–185.
16. Plat J & Mensink RP (2002) Increased intestinal *ABCA1* expression contributes to the decrease in cholesterol absorption after plant stanol consumption. *FASEB J* **16**, 1248–1253.
17. de Jong A, Plat J & Mensink RP (2003) Metabolic effects of plant sterols and stanols (review). *J Nutr Biochem* **14**, 362–369.
18. Hegele RA & Robinson JF (2005) ABC transporters and sterol absorption. *Curr Drug Targets Cardiovasc Haematol Disord* **5**, 31–37.
19. Calpe-Berdiel L, Escolà-Gil JC & Blanco-Vaca F (2009) New insights into the molecular actions of plant sterols and stanols in cholesterol metabolism. *Atherosclerosis* **203**, 18–31.
20. Kidambi S & Patel SB (2008) Cholesterol and non-cholesterol sterol transporters: ABCG5, ABCG8 and NPC1L1: a review. *Xenobiotica* **38**, 1119–1139.
21. Castro IA, Barroso LP & Sinnecker P (2005) Functional foods for coronary heart disease risk reduction: a meta-analysis using a multivariate approach. *Am J Clin Nutr* **82**, 32–40.
22. de Graaf J & Stalenhoef AF (2000) Use of margarine fortified with phytosterols as a therapeutic food (article in Dutch). *Ned Tijdschr Geneesk* **144**, 918–921.
23. Abumweis SS, Barake R & Jones PJ (2008) Plant sterols/stanols as cholesterol lowering agents: a meta-analysis of randomized controlled trials. *Food Nutr Res* **52**, (publication 18 August 2008).
24. Demonty I, Ras RT, van der Knaap HC, *et al.* (2009) Continuous dose–response relationship of the LDL-cholesterol-lowering effect of phytosterol intake. *J Nutr* **139**, 271–284.
25. United States Food and Drug Administration (2003) FDA Letter Regarding Enforcement Discretion With Respect to Expanded Use of an Interim Health Claim Rule About Plant Sterol/Stanol Esters and Reduced Risk of Coronary Heart Disease. <http://www.fda.gov/Food/LabelingNutrition/LabelClaims/HealthClaimsMeetingSignificantScientificAgreementSSA/ucm074779.htm> (accessed 17 April 2008).
26. United States Food and Drug Administration (2000) Interim Final Rule – Food Labeling: Health Claims: Plant Sterol/Stanol Esters and Coronary Heart Disease. <http://www.fda.gov/Food/LabelingNutrition/LabelClaims/HealthClaimsMeetingSignificantScientificAgreementSSA/default.htm>
27. Hallikainen MA, Sarkkinen ES, Gylling H, *et al.* (2000) Comparison of the effects of plant sterol ester and plant stanol ester-enriched margarines in lowering serum cholesterol concentrations in hypercholesterolaemic subjects on a low-fat diet. *Eur J Clin Nutr* **54**, 715–725.
28. European Parliament and the Council of the European Union (2006) Regulation (EC) No 1924/2006 of the European Parliament and the Council of 20 December 2006 on nutrition and health claims made on foods. <http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2007:012:0003:0018:EN:PDF>
29. European Food Safety Authority (2008) Plant Sterols and Blood Cholesterol – Scientific substantiation of a health claim related to plant sterols and lower/reduced blood cholesterol and reduced risk of (coronary) heart disease pursuant to Article 14 of Regulation (EC) No 1924/2006. [http://www.efsa.europa.eu/EFSA/efsa\\_locale-1178620753812\\_121190205\\_4931.htm](http://www.efsa.europa.eu/EFSA/efsa_locale-1178620753812_121190205_4931.htm) (accessed 17 April 2008).
30. European Food Safety Authority (2008) Scientific substantiation of a health claim related to plant stanol esters and lower/reduced blood cholesterol and reduced risk of (coronary) heart disease pursuant to Article 14 of Regulation (EC) No 1924/2006. [http://www.efsa.europa.eu/cs/BlobServer/Scientific\\_Opinion/nda\\_op\\_ej825\\_art\\_14\\_0038\\_plant\\_stanol\\_ester\\_en.pdf?ssbinary=true](http://www.efsa.europa.eu/cs/BlobServer/Scientific_Opinion/nda_op_ej825_art_14_0038_plant_stanol_ester_en.pdf?ssbinary=true)
31. Verhagen H (2008) The current status of nutrition and health claims in Europe. *J Clin Biochem Nutr* **43**, Suppl. 1, 1–5.
32. European Parliament and the Council of the European Union (1997) Regulation (EC) No 258/97 of the European Parliament and of the Council of 27 January 1997 concerning novel foods and novel food ingredients. <http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:31997R0258:EN:HTML>
33. European Union Science Committee on Food (2000) Opinion of the Scientific Committee on Food on a Request for the Safety Assessment of the Use of Phytosterol Esters in Yellow Fat Spreads. [http://ec.europa.eu/food/fs/sc/scf/out56\\_en.pdf](http://ec.europa.eu/food/fs/sc/scf/out56_en.pdf)
34. Verhagen H, Te Boekhorst J, Kamps L, *et al.* (2009) Novel foods: an explorative study into their grey area. *Br J Nutr* **101**, 1270–1277.
35. Vanhanen H (1994) Cholesterol malabsorption caused by sitostanol ester feeding and neomycin in pravastatin-treated hypercholesterolaemic patients. *Eur J Clin Pharmacol* **47**, 169–176.
36. Ketomaki A, Gylling H & Miettinen TA (2005) Non-cholesterol sterols in serum, lipoproteins, and red cells in statin-treated FH subjects off and on plant stanol and sterol ester spreads. *Clin Chim Acta* **353**, 75–86.
37. Blair SN, Capuzzi DM, Gottlieb SO, *et al.* (2000) Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy. *Am J Cardiol* **86**, 46–52.
38. Goldberg AC, Ostlund RE Jr, Bateman JH, *et al.* (2006) Effect of plant stanol tablets on low-density lipoprotein cholesterol lowering in patients on statin drugs. *Am J Cardiol* **97**, 376–379.
39. Richter WO (1996) Treatment of severe hypercholesterolemia with a combination of  $\beta$ -sitosterol and lovastatin. *Curr Ther Res* **57**, 497–505.
40. Simons LA (2002) Additive effect of plant sterol-ester margarine and cervastatin in lowering low-density lipoprotein cholesterol in primary hypercholesterolemia. *Am J Cardiol* **90**, 737–740.
41. De Jong A, Plat J, Bast A, *et al.* (2007) Effects of plant sterol and stanol ester consumption on lipid metabolism, antioxidant status and markers of oxidative stress, endothelial function and low-grade inflammation in patients on current statin treatment. *Eur J Clin Nutr* **62**, 263–273.
42. Castro Cabezas M, de Vries JH, Van Oostrom AJ, *et al.* (2006) Effects of a stanol-enriched diet on plasma cholesterol and triglycerides in patients treated with statins. *J Am Diet Assoc* **106**, 1564–1569.
43. Gylling H, Radhakrishnan R & Miettinen TA (1997) Reduction of serum cholesterol in postmenopausal women with previous myocardial infarction and cholesterol malabsorption induced by dietary sitostanol ester margarine: women and dietary sitostanol. *Circulation* **96**, 4226–4231.
44. Vuorio AF, Gylling H, Turtola H, *et al.* (2000) Stanol ester margarine alone and with simvastatin lowers serum cholesterol in families with familial hypercholesterolemia caused by the FH-North Karelia mutation. *Arterioscler Thromb Vasc Biol* **20**, 500–506.
45. de Jong N, Zuur A, Wolfs MC, *et al.* (2007) Exposure and effectiveness of phytosterol/stanol-enriched margarines. *Eur J Clin Nutr* **61**, 1407–1415.

46. Wolfs M, de Jong N, Ocke MC, *et al.* (2006) Effectiveness of customary use of phytosterol/stanol enriched margarines on blood cholesterol lowering. *Food Chem Toxicol* **44**, 1682–1688.
47. Amundsen AL, Ntanios F, Put N, *et al.* (2004) Long-term compliance and changes in plasma lipids, plant sterols and carotenoids in children and parents with FH consuming plant sterol ester-enriched spread. *Eur J Clin Nutr* **58**, 1612–1620.
48. Neil HA, Meijer GW & Roe LS (2001) Randomised controlled trial of use by hypercholesterolaemic patients of a vegetable oil sterol-enriched fat spread. *Atherosclerosis* **156**, 329–337.
49. O'Neill FH, Brynes A, Mandeno R, *et al.* (2004) Comparison of the effects of dietary plant sterol and stanol esters on lipid metabolism. *Nutr Metab Cardiovasc Dis* **14**, 133–142.
50. Gylling H & Miettinen TA (2002) Baseline intestinal absorption and synthesis of cholesterol regulate its response to hypo-lipidaemic treatments in coronary patients. *Atherosclerosis* **160**, 477–481.
51. Katan MB, Grundy SM, Jones P, *et al.* (2003) Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. *Mayo Clin Proc* **78**, 965–978.
52. Patel MD & Thompson PD (2006) Phytosterols and vascular disease. *Atherosclerosis* **186**, 12–19.
53. Heinemann T, Axtmann G & von Bergmann K (1993) Comparison of intestinal absorption of cholesterol with different plant sterols in man. *Eur J Clin Invest* **23**, 827–831.
54. Goldstein MR, Mascitelli L & Pezzetta F (2008) Statins, plant sterol absorption, and coronary risk. *J Clin Lipidol* **2**, 304–305.
55. John S, Sorokin AV & Thompson PD (2007) Phytosterols and vascular disease. *Curr Opin Lipidol* **18**, 35–40.
56. Lea LJ & Hepburn PA (2006) Safety evaluation of phytosterol-esters. Part 9: Results of a European post-launch monitoring programme. *Food Chem Toxicol* **44**, 1213–1222.
57. Van Horn L, McCain M, Kris-Etherton PM, *et al.* (2008) The evidence for dietary prevention and treatment of cardiovascular disease. *J Am Diet Assoc* **108**, 287–331.
58. Anderson JW, Allgood LD, Lawrence A, *et al.* (2000) Cholesterol-lowering effects of psyllium intake adjunctive to diet therapy in men and women with hypercholesterolemia: meta-analysis of 8 controlled trials. *Am J Clin Nutr* **71**, 472–479.
59. Bell LP, Hectorn KJ, Reynolds H, *et al.* (1990) Cholesterol-lowering effects of soluble-fiber cereals as part of a prudent diet for patients with mild to moderate hypercholesterolemia. *Am J Clin Nutr* **52**, 1020–1026.
60. Chen J, He J, Wildman RP, *et al.* (2006) A randomized controlled trial of dietary fiber intake on serum lipids. *Eur J Clin Nutr* **60**, 62–68.
61. Davidson MH, Dugan LD, Burns JH, *et al.* (1991) The hypocholesterolemic effects of  $\beta$ -glucan in oatmeal and oat bran. A dose-controlled study. *JAMA* **265**, 1833–1839.
62. Naumann E, van Rees AB, Onning G, *et al.* (2006)  $\beta$ -Glucan incorporated into a fruit drink effectively lowers serum LDL-cholesterol concentrations. *Am J Clin Nutr* **83**, 601–605.
63. Van Horn L, Emidy LA, Liu KA, *et al.* (1988) Serum lipid response to a fat-modified, oatmeal-enhanced diet. *Prev Med* **17**, 377–386.
64. Butt MS, Shahzadi N, Sharif MK, *et al.* (2007) Guar gum: a miracle therapy for hypercholesterolemia, hyperglycemia and obesity. *Crit Rev Food Sci Nutr* **47**, 389–396.
65. Todd PA, Benfield P & Goa KL (1990) Guar gum. A review of its pharmacological properties, and use as a dietary adjunct in hypercholesterolaemia. *Drugs* **39**, 917–928.
66. Brown L, Rosner B, Willett WW, *et al.* (1999) Cholesterol-lowering effects of dietary fiber: a meta-analysis. *Am J Clin Nutr* **69**, 30–42.
67. Vergara-Jimenez M, Furr H & Fernandez ML (1999) Pectin and psyllium decrease the susceptibility of LDL to oxidation in guinea pigs. *J Nutr Biochem* **10**, 118–124.
68. Theuwissen E & Mensink RP (2008) Water-soluble dietary fibers and cardiovascular disease. *Physiol Behav* **94**, 285–292.
69. United States Food and Drug Administration (1997) Food Labeling: Health Claims; Oats and Coronary Heart Disease; Final Rule. <http://www.fda.gov/Food/LabelingNutrition/LabelClaims/HealthClaimsMeetingSignificantScientificAgreementSSA/ucm074719.htm> (accessed 25 June 2008).
70. United States Food and Drug Administration (1998) Federal Register 63 FR 8103, February 18, 1998 – Food Labeling: Health Claims; Soluble Fiber From Certain Foods and Coronary Heart Disease, Final Rule. <http://www.fda.gov/Food/LabelingNutrition/LabelClaims/HealthClaimsMeetingSignificantScientificAgreementSSA/ucm074351.htm> (accessed 25 June 2008).
71. Joint Health Claims Initiative (2006) Generic health claim for oats and blood cholesterol 06-05-04. <http://www.jhci.org.uk/approv/Final%20expert%20report%20050606.doc>
72. Swedish Nutrition Foundation (2004) Swedish Nutrition Foundation, Health Claims. In the Labelling and Marketing of Food Products. The Food Sector's Code of Practice. [http://www.snf.ideal.se/snf/en/rh/SweCode\\_2004.pdf](http://www.snf.ideal.se/snf/en/rh/SweCode_2004.pdf)
73. Voedingscentrum (2005) Assessment Report 19-04-05. <http://www.voedingscentrum.nl/NR/rdonlyres/69A98772-DC6D-4057-9D34-F2B90B152836/0/beoordelingsrapportPr%C3%83%C2%B3FIT.pdf>
74. Richter WO, Jacob BG & Schwandt P (1991) Interaction between fibre and lovastatin. *Lancet* **338**, 706.
75. Uusitupa M, Ebeling T, Happonen P, *et al.* (1991) Combination therapy with lovastatin and guar gum versus lovastatin and cholestyramine in treatment of hypercholesterolemia. *J Cardiovasc Pharmacol* **18**, 496–503.
76. Uusitupa MI, Miettinen TA, Happonen P, *et al.* (1992) Lathosterol and other noncholesterol sterols during treatment of hypercholesterolemia with lovastatin alone and with cholestyramine or guar gum. *Arterioscler Thromb* **12**, 807–813.
77. Moreyra AE, Wilson AC & Koraym A (2005) Effect of combining psyllium fiber with simvastatin in lowering cholesterol. *Arch Intern Med* **165**, 1161–1166.
78. Jayaram S, Prasad HB, Sovani VB, *et al.* (2007) Randomised study to compare the efficacy and safety of isapgol plus atorvastatin v. atorvastatin alone in subjects with hypercholesterolaemia. *J Indian Med Assoc* **105**, 142–145, 150.
79. Agrawal AR, Tandon M & Sharma PL (2007) Effect of combining viscous fibre with lovastatin on serum lipids in normal human subjects. *Int J Clin Pract* **61**, 1812–1818.
80. Borel P (2003) Factors affecting intestinal absorption of highly lipophilic food microconstituents (fat-soluble vitamins, carotenoids and phytosterols). *Clin Chem Lab Med* **41**, 979–994.
81. Riedl J, Linseisen J, Hoffmann J, *et al.* (1999) Some dietary fibers reduce the absorption of carotenoids in women. *J Nutr* **129**, 2170–2176.
82. Garcia JJ, Fernandez N, Diez MJ, *et al.* (2000) Influence of two dietary fibers in the oral bioavailability and other pharmacokinetic parameters of ethinyloestradiol. *Contraception* **62**, 253–257.
83. Hokanson JE & Austin MA (1996) Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. *J Cardiovasc Risk* **3**, 213–219.
84. Harris WS, Miller M, Tighe AP, *et al.* (2007) Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. *Atherosclerosis* **197**, 12–24.
85. Davidson MH (2006) Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. *Am J Cardiol* **98**, 27i–33i.
86. Harris WS & Bulchandani D (2006) Why do omega-3 fatty acids lower serum triglycerides? *Curr Opin Lipidol* **17**, 387–393.



87. Connor SL & Connor WE (1997) Are fish oils beneficial in the prevention and treatment of coronary artery disease? *Am J Clin Nutr* **66**, Suppl. 4, 1020S–1031S.
88. Demaison L & Moreau D (2002) Dietary *n*-3 polyunsaturated fatty acids and coronary heart disease-related mortality: a possible mechanism of action. *Cell Mol Life Sci* **59**, 463–477.
89. Balk EM, Lichtenstein AH, Chung M, *et al.* (2006) Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. *Atherosclerosis* **189**, 19–30.
90. Harris WS (1989) Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review. *J Lipid Res* **30**, 785–807.
91. McKenney JM & Sica D (2007) Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia. *Am J Health Syst Pharm* **64**, 595–605.
92. United States Food and Drug Administration (2004) FDA Announces Qualified Health Claims for Omega-3 Fatty Acids. <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108351.htm> (accessed 15 July 2008).
93. Contacos C, Barter PJ & Sullivan DR (1993) Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia. *Arterioscler Thromb* **13**, 1755–1762.
94. Chan DC, Watts GF, Barrett PH, *et al.* (2002) Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. *Diabetes* **51**, 2377–2386.
95. Chan DC, Watts GF, Mori TA, *et al.* (2002) Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity. *Eur J Clin Invest* **32**, 429–436.
96. Davidson MH, Macariola-Coad JR, McDonald AM, *et al.* (1997) Separate and joint effects of marine oil and simvastatin in patients with combined hyperlipidemia. *Am J Cardiol* **80**, 797–798.
97. Davidson MH, Stein EA, Bays HE, *et al.* (2007) Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. *Clin Ther* **29**, 1354–1367.
98. Durrington PN, Bhatnagar D, Mackness MI, *et al.* (2001) An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. *Heart* **85**, 544–548.
99. Grekas D, Kassimatis E, Makedou A, *et al.* (2001) Combined treatment with low-dose pravastatin and fish oil in post-renal transplantation dyslipidemia. *Nephron* **88**, 329–333.
100. Hong H, Xu ZM, Pang BS, *et al.* (2004) Effects of simvastatin combined with omega-3 fatty acids on high sensitive C-reactive protein, lipidemia, and fibrinolysis in patients with mixed dyslipidemia. *Chin Med Sci J* **19**, 145–149.
101. Meyer BJ, Hammervold T, Rustan AC, *et al.* (2007) Dose-dependent effects of docosahexaenoic acid supplementation on blood lipids in statin-treated hyperlipidaemic subjects. *Lipids* **42**, 109–115.
102. Nakamura N, Hamazaki T, Ohta M, *et al.* (1999) Joint effects of HMG-CoA reductase inhibitors and eicosapentaenoic acids on serum lipid profile and plasma fatty acid concentrations in patients with hyperlipidemia. *Int J Clin Lab Res* **29**, 22–25.
103. Nordøy A, Bønaa KH, Nilsen H, *et al.* (1998) Effects of simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia. *J Intern Med* **243**, 163–170.
104. Yokoyama M, Origasa H, Matsuzaki M, *et al.* (2007) Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. *Lancet* **369**, 1090–1098.
105. Nordøy A, Hansen JB, Brox J, *et al.* (2001) Effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipemia in patients with combined hyperlipemia. *Nutr Metab Cardiovasc Dis* **11**, 7–16.
106. Aligeti VR, Gandhi M, Braden R, *et al.* (2007) Effect of combination lipid-modifying therapy on the triglyceride lowering effect of fish oil. *Am J Med Sci* **333**, 168–172.
107. Sandset PM, Lund H, Norseth J, *et al.* (1991) Treatment with hydroxymethylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system. *Arterioscler Thromb* **11**, 138–145.
108. Balestrieri GP, Maffi V, Sleiman I, *et al.* (1996) Fish oil supplementation in patients with heterozygous familial hypercholesterolemia. *Recenti Prog Med* **87**, 102–105.
109. Bays H (2006) Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. *Am J Cardiol* **98**, 71i–76i.
110. Bays HE (2007) Safety considerations with omega-3 fatty acid therapy. *Am J Cardiol* **99**, 35C–43C.
111. Yang H & Kenny A (2007) The role of fish oil in hypertension. *Conn Med* **71**, 533–538.
112. Littarru GP & Langsjoen P (2007) Coenzyme Q<sub>10</sub> and statins: biochemical and clinical implications. *Mitochondrion* **7**, Suppl., S168–S174.
113. Nawarskas JJ (2005) HMG-CoA reductase inhibitors and coenzyme Q<sub>10</sub>. *Cardiol Rev* **13**, 76–79.
114. Caso G, Kelly P, McNurlan MA, *et al.* (2007) Effect of coenzyme Q<sub>10</sub> on myopathic symptoms in patients treated with statins. *Am J Cardiol* **99**, 1409–1412.
115. Levy HB & Kohlhaas HK (2006) Considerations for supplementing with coenzyme Q<sub>10</sub> during statin therapy. *Ann Pharmacother* **40**, 290–294.
116. Marcoff L & Thompson PD (2007) The role of coenzyme Q<sub>10</sub> in statin-associated myopathy: a systematic review. *J Am Coll Cardiol* **49**, 2231–2237.
117. Pepe S, Marasco SF, Haas SJ, *et al.* (2007) Coenzyme Q<sub>10</sub> in cardiovascular disease. *Mitochondrion* **7**, Suppl., S154–S167.
118. Bargossi AM, Grossi G, Fiorella PL, *et al.* (1994) Exogenous CoQ<sub>10</sub> supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors. *Mol Aspects Med* **15**, Suppl., s187–s193.
119. Young JM, Florkowski CM, Molyneux SL, *et al.* (2007) Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. *Am J Cardiol* **100**, 1400–1403.
120. Langsjoen PH, Langsjoen JO, Langsjoen AM, *et al.* (2005) Treatment of statin adverse effects with supplemental coenzyme Q<sub>10</sub> and statin drug discontinuation. *Biofactors* **25**, 147–152.
121. Thompson PD, Clarkson P & Karas RH (2003) Statin-associated myopathy. *JAMA* **289**, 1681–1690.
122. Ucar M, Mjorndal T & Dahlqvist R (2000) HMG-CoA reductase inhibitors and myotoxicity. *Drug Saf* **22**, 441–457.
123. Hidaka T, Fujii K, Funahashi I, *et al.* (2008) Safety assessment of coenzyme Q<sub>10</sub> (CoQ<sub>10</sub>). *Biofactors* **32**, 199–208.
124. Mabuchi H, Nohara A, Kobayashi J, *et al.* (2007) Effects of CoQ<sub>10</sub> supplementation on plasma lipoprotein lipid, CoQ<sub>10</sub> and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: a randomized double-blind study. *Atherosclerosis* **195**, e182–e189.
125. Kromer A & Moosmann B (2009) Statin-induced liver injury involves cross-talk between cholesterol and selenoprotein biosynthetic pathways. *Mol Pharmacol* **75**, 1421–1429.
126. Moosmann B & Behl C (2004) Selenoprotein synthesis and side-effects of statins. *Lancet* **363**, 892–894.
127. Arduini A, Pescechera A, Giannesi F, *et al.* (2004) Improvement of statin-associated myotoxicity by L-carnitine. *J Thromb Haemost* **2**, 2270–2271.

128. Link E, Parish S, Armitage J, *et al.* (2008) *SLCO1B1* variants and statin-induced myopathy – a genome-wide study. *N Engl J Med* **359**, 789–799.
129. Schaeffer L, Gohlke H, Muller M, *et al.* (2006) Common genetic variants of the *FADS1 FADS2* gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids. *Hum Mol Genet* **15**, 1745–1756.
130. Tanaka T, Shen J, Abecasis GR, *et al.* (2009) Genome-wide association study of plasma polyunsaturated fatty acids in the InCHIANTI Study. *PLoS Genet* **5**, e1000338.
131. Xie L & Innis SM (2008) Genetic variants of the *FADS1 FADS2* gene cluster are associated with altered (*n*-6) and (*n*-3) essential fatty acids in plasma and erythrocyte phospholipids in women during pregnancy and in breast milk during lactation. *J Nutr* **138**, 2222–2228.
132. Manolio TA (2009) Cohort studies and the genetics of complex disease. *Nat Genet* **41**, 5–6.
133. Herings RMC, Leufkens HGM, Heerdink ER, *et al.* (2002) *Chronic Pharmacotherapy Forever*. Utrecht, The Netherlands: PHARMO.
134. Mantel-Teeuwisse AK, Goettsch WG, Klungel OH, *et al.* (2004) Long term persistence with statin treatment in daily medical practice. *Heart* **90**, 1065–1066.
135. De Jong N, Ros MM, Ocke MC, *et al.* (2008) A general post-launch monitoring framework for functional foods tested with the phytosterol/-stanol case. *Trends Food Sci Tech* **19**, 535–545.
136. Commission of the European Communities (2009) Commission Regulation (EC) No 983/2009 of 21 October 2009 on the authorisation and refusal of authorisation of certain health claims made on food and referring to the reduction of disease risk and to children's development and health. <http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:277:0003:0012:EN:PDF>
137. European Food Safety Authority (2009) Scientific Opinion on the substantiation of health claims related to beta-glucans and maintenance of normal blood cholesterol concentrations (ID 754, 755, 757, 801, 1465, 2934) and maintenance or achievement of a normal body weight (ID 820, 823) pursuant to Article 13(1) of Regulation (EC) No 1924/2006 [http://www.efsa.europa.eu/EFSA/Scientific\\_Opinion/nda\\_op\\_ej1254\\_art13\(1\)\\_beta\\_glucans\\_related\\_claims\\_summary\\_en,0.pdf%3Fssbinary%3Dtrue](http://www.efsa.europa.eu/EFSA/Scientific_Opinion/nda_op_ej1254_art13(1)_beta_glucans_related_claims_summary_en,0.pdf%3Fssbinary%3Dtrue)